Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 9, 2010

Ortho-McNeil-Janssen Taps Anchor for Pepducin Technology

Ortho-McNeil-Janssen Taps Anchor for Pepducin Technology

Deal includes Anchor’s preclinical gpr39-targeting program and $480 million in milestones. [© lily - Fotolia.com]

  • Ortho-McNeil-Janssen Pharmaceuticals (OMJPI) is leveraging Anchor Therapeutics’ pepducin technology to develop GPCR-targeted therapeutics for oncology and metabolic disorders. Anchor will receive an up-front payment as well as  research support and could be eligible for development and regulatory milestone payments of up to $480 million.

    Anchor and OMJPI will work jointly to discover and optimize preclinical candidates against GPCR targets. This will include Anchor’s program targeting gpr39, a GPCR involved in metabolic diseases. OMJPI will assume responsibility for development and commercialization.

    Pepducins are lipidated peptides designed to be allosteric modulators for GPCR targets. They are composed of a short peptide derived from a GPCR intracellular loop linked to a lipid moiety. This structure allows pepducins to anchor in the cell membrane and target the GPCR protein via a unique intracellular allosteric mechanism, according to Anchor Therapeutics.

    Anchor also has a collaboration with Novartis, which was initiated in December 2008. Novartis agreed to milestones totaling over $200 million for licensing options to candidates against a specific GPCR target that Anchor would develop.  Investigational pepducins under this partnership are being developed for cardiovascular, gastrointestinal, and inflammatory disorders.



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »